Kyverna Therapeutics, Inc.
KYTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $34 | $53 | $57 | $97 |
| Short-Term Investments | $137 | $158 | $186 | $189 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $3 | $5 | $5 |
| Total Curr. Assets | $175 | $214 | $248 | $291 |
| Property Plant & Equip (Net) | $6 | $8 | $9 | $11 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $5 | $5 | $4 | $5 |
| Total NC Assets | $12 | $12 | $13 | $16 |
| Other Assets | $0 | $0 | $0 | -$2 |
| Total Assets | $187 | $227 | $261 | $305 |
| Liabilities | – | – | – | – |
| Payables | $3 | $10 | $8 | $5 |
| Short-Term Debt | $4 | $4 | $4 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $27 | $26 | $21 | $25 |
| Total Curr. Liab. | $34 | $40 | $33 | $34 |
| LT Debt | $1 | $2 | $3 | $4 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $1 | $2 | $3 | $4 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $6 | $7 | $8 |
| Total Liabilities | $35 | $42 | $37 | $38 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$387 | -$350 | -$308 | -$264 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $539 | $535 | $532 | $530 |
| Total Equity | $152 | $184 | $224 | $267 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $187 | $227 | $261 | $305 |
| Net Debt | -$29 | -$48 | -$50 | -$88 |